Moderna chief executive Stéphane Bancel said early data suggests the bivalent shot could provide more long-lasting protection against variants of concern than the company’s original formula alone.
Moderna’s Booster Shot Targeting Omicron And Original Strain Could Be Available Late Summer After Promising Trials
